Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.

Mr. Sebastien  Delarive

Chief Business Officer of Ypsomed Diabetes Care

Ms. Ulrike  Bauer

Chief Business Officer of Ypsomed Delivery Systems

Mr. Simon  Michel

Member of the Board

Mr. Michael  Zaugg

Chief Corporate Officer

Mr. Niklaus  Ramseier

Chief Financial Officer

Mr. Frank  Mengis

Chief Operating Officer

Thomas  Kutt

Head of Investor Relations

Dr. Nicolas  Meyer

Chief Legal Officer

Ypsomed Holding AG

Ypsomed Holding AG Struktura zarządzania

Informacje o kierownictwie